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A combined pre-clinical meta-
analysis and randomized 
confirmatory trial approach 
to improve data validity for 
therapeutic target validation
Pamela WM Kleikers1,*, Carlijn Hooijmans2,*, Eva Göb3,*, Friederike Langhauser3, 
Sarah SJ Rewell4, Kim Radermacher1, Merel Ritskes-Hoitinga2, David W Howells4, 
Christoph Kleinschnitz3,† & Harald HHW Schmidt1,†
Biomedical research suffers from a dramatically poor translational success. For example, in ischemic 
stroke, a condition with a high medical need, over a thousand experimental drug targets were 
unsuccessful. Here, we adopt methods from clinical research for a late-stage pre-clinical meta-
analysis (MA) and randomized confirmatory trial (pRCT) approach. A profound body of literature 
suggests NOX2 to be a major therapeutic target in stroke. Systematic review and MA of all available 
NOX2-/y studies revealed a positive publication bias and lack of statistical power to detect a relevant 
reduction in infarct size. A fully powered multi-center pRCT rejects NOX2 as a target to improve 
neurofunctional outcomes or achieve a translationally relevant infarct size reduction. Thus stringent 
statistical thresholds, reporting negative data and a MA-pRCT approach can ensure biomedical data 
validity and overcome risks of bias.
Medical innovation is impacted by major quality and reproducibility issues of basic science data1–3 that 
then impact on further clinical development4,5. These issues are on top of a general notion that animal 
models may be less predictive than we thought6,7. It has been shown that this is partly a consequence of 
suboptimal study design8 and analysis9, and poor reporting10–12.
In stroke and its preclinical research, the situation is particularly alarming13,14. Stroke is the third 
cause of death and number one reason for chronic disability. Despite this high medical need only one 
drug (recombinant tissue plasminogen activator) is registered to treat ischemic stroke; however, it has 
limited efficacy15 and over 30 contraindications, so that 85% of all stroke patients remain without any 
acute drug treatment. This single “successful” stroke drug development stands in sharp contrast to 1,026 
failed experimental stroke targets14,16, despite several roundtable recommendations to improve the qual-
ity of preclinical stroke research17,18 including advanced study designs19. Consequently, industry scientists 
have left target discovery and drug development for stroke almost completely non-investigated. Recently, 
this has led to proposals that preclinical research needs to improve in quality by adopting elements of 
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clinical research, including multi-center studies, randomization, blinding and a priori power calculation 
for relevant outcomes17,20,21.
With respect to relevant pre-clinical outcomes, a shift is necessary from surrogates such as infarct 
size to measurement of neurological function; with respect to the therapeutic approach, patients need a 
shift from vascular re-canalization to adding on neuroprotection22. Oxidative stress or the occurrence of 
reactive oxygen species (ROS) in increased amounts, in unphysiological places or with unphysiological 
chemistry, has been suggested to play a major role in neurodegeneration upon ischemic stroke23–25. Even 
under conditions of ischemia26, ROS have both protective and deleterious effects27, which explains why 
global anti-oxidant therapy has failed28–30. A more promising approach is to target oxidative stress in a 
manner that leaves essential, physiological ROS formation untouched and inhibits only disease-relevant 
enzymatic sources30–32. As such a source of ROS, NADPH oxidases (NOX) stand out as they represent 
the only enzyme family that has ROS formation as its only known function. Most prominently NOX233 
has been suggested to be a prime target in stroke34, whilst our own previous observations24 profoundly 
disagreed. Nine other publications (using a total of 159 animals), however, investigated NOX2-/y mice 
to conclude a major contribution of this enzyme to infarct size by up to 60%23,35–42. As a point of con-
cern, NOX2 is known to play a major role in innate immunity and its deletion causes severe immune 
deficiencies, in particular with common comorbidities such as diabetes mellitus43. Because of these risks, 
the benefit of inhibiting NOX2 in stroke would need to be validated beyond doubt before entering a 
discovery program or clinical trials.
Adoption of large-scale collaborative research has been suggested as a means to improve the success 
rate and validity of such pre-clinical target validation. Clearly this is not feasible for every exploratory 
pre-clinical trial. However, in order to make a valid target statement, we here learn from the successes of 
clinical research and implement for the first time a recent suggestion21 to conduct pharmacological target 
validation research as pre-clinical randomized confirmatory trials (pRCTs). We also combine this with a 
systematic review (SR) and meta-analysis (MA) that is then re-run after the pRCT. The outcomes of the 
SR-MA-pRCT-MA approach have implications for stroke research and late-stage preclinical biomedical 
research in general.
Methods
Animals. NOX2 deficient mice (NOX2 KO, stock #002365) from C57Bl/6J background and corre-
sponding age-matched C57Bl/6J control mice (stock #000664) with an SPF health status were purchased 
from Jackson Laboratories (Bar Harbor, ME, USA). In a previous study24 we already tested young male 
(6–8 weeks, 20–25 grams) mice. We therefore extended our inclusion criteria by using also female (8–10 
weeks, 18–21 grams) and older (18–20 weeks, 26–31 grams) mice. All experiments were approved by 
the local animal ethics committees of Maastricht (DEC 2011-106) and Würzburg (69/08). Animals were 
socially housed in IVC cages under controlled conditions (22 °C, 55–65% humidity, 12 h light-dark cycle, 
in type II IVC macrolon cages up to 3 mice in Würzburg, up to 4 males and 5 females in Maastricht; 
type III, up to 10 in Würzburg), and were allowed free access to water and standard laboratory chow 
(Maastricht, R/M-H, ssniff, Soest, Germany; Würzburg, Altromin standard diet, Altromin Spezialfutter 
GmbH & Co. KG, Lage, Germany).
Systematic review. The present review was based on published results of animal studies on the role 
of NADPH oxidase 1 and/or 2 in experimental ischemic stroke. PubMed and EMBASE were searched 
for original papers and conference abstracts concerning the effects of NADPH oxidase 1 and/or 2 on 
experimental stroke until October 23, 2013. The search strategy involved the following 3 search compo-
nents: ischemic stroke, NADPH oxidase 1 and/or 2 and animals (for the complete search strategy, see 
Supplementary Table 1). For detecting animal studies, search filters developed by SYRCLE were used44,45. 
No language restriction was used. Our search strategy identified 562 records in PubMed and 812 records 
in EMBASE. After removal of duplicates, a total of 1089 records were screened a first time based on 
title and abstract, excluding non-in-vivo papers, papers not using ischemic stroke and papers using an 
unspecific inhibitor of NOX or combining an inhibitor with other therapies. 25 articles were included 
for full text screening, of which 22 addressed NOX2 and 4 articles addressed NOX1. Two independent 
researchers (PWMK and SSJR) screened all titles and abstracts for the inclusion criteria. Studies were 
included if they 1) investigated the role of NADPH oxidase 1 and/or 2 on the infarct size and neuro-
logical scoring after experimental focal ischemic stroke using either genetic or specific pharmacological 
inhibition of these NOX isoforms; 2) were performed in animals in vivo; 3) resulted in an original full 
paper or conference abstract which presented unique data. Papers were excluded when unspecific NOX 
inhibitors such as apocynin46,47 were used or when NOX inhibition was combined with other drugs/
therapies. The in– and exclusion criteria and methods of analysis were specified in advance and docu-
mented in a protocol.
After full text assessment, thirteen papers for the NOX2 study (using in total 162 WT and 171 
KO mice) and four papers for the NOX1 study (using in total 69 WT and 141 KO mice), and 16 rats 
(8 with and 8 without siRNA) were included (Supplementary Fig. 1) for qualitative and quantitative 
analyses23,24,36–42,48-53.
www.nature.com/scientificreports/
3Scientific RepoRts | 5:13428 | DOi: 10.1038/srep13428
Study characteristics. From the included studies, bibliographic data such as authors, year of publica-
tion, journal of publication and language were registered. Study characteristics concerning study design 
were extracted and summarized in Supplementary Table 2: species, strain (including genetic KO), gender, 
age and weight of the animals used; type of anesthesia; method and duration of ischemia; duration of 
reperfusion (timing of outcome measurements), type of inhibitor used; method of culling; method of 
infarct size measurement and neurological outcome assessment; (reason for) dropouts and mortality. All 
studies except one, used NOX KO mice as experimental animals, with one study using both genders, 
the rest only males. One study used rats treated with siRNA. All studies used the middle cerebral artery 
(MCA) occlusion model, sixteen studies occluded transiently allowing reperfusion afterwards, and two 
studies occluded the MCA permanently (one study used both permanent and transient ischemia). The 
duration of the ischemia and the reperfusion varied greatly among studies (5 to 120 minutes). Three 
different methods of infarct size measurement and three different scoring systems for the neurological 
assessment were used. All retrieved data sets could be taken into account for the meta-analysis regarding 
infarct size. Neurological scoring was measured in seven out of thirteen NOX2 papers and three out of 
four NOX1 studies.
Assessment of methodological quality and risk of bias. Study quality and risk of bias in the 
included studies was independently assessed by two reviewers (PWMK and CH), using a predefined 
9-point rating system (based on54) (see Supplementary Table 3 and legend for details). Seven items were 
assessed to study risk of bias. A “yes” judgment indicates a low risk of bias; a “no” judgment indicates 
high risk of bias; the judgment was “unclear” if insufficient details had been reported to assess the risk 
of bias properly. The possible presence of selection bias (items 1, 2 and 4) detection bias (items 6, 7 
and 8) performance bias (item 5) and attrition bias (items 9) were judged. Because of poor reporting 
of essential details in animal studies, we also included two reporting items: we assessed whether it had 
been reported if the experiments were randomized or blinded at any level (item 1 and 3). Disagreements 
were solved by discussion.
Meta-analysis. Infarct size and neurological outcome were included in the meta-analysis. Data were 
extracted if raw data or group averages, standard deviation (SD) or standard error (SE), and number of 
animals per group (n) were reported, or could be recalculated. All authors were contacted to contribute 
their original data to the meta-analysis. From two publications, no response from authors was obtained. 
For one publication, authors could not recollect their original data. In these cases, data were extracted 
from the text, or if presented only graphically, measured using a universal on-screen digitizer (Universal 
Desktop Ruler). CAMARADES consortium (http://www.dcn.ed.ac.uk/camarades//default.htm) suggests 
the use of normalized mean difference (NMD), which requires correcting for sham values. However, 
of all thirteen included NOX2 papers, only three reported the use of shams, but not for all groups and 
all outcome parameters35,38,42. None of the others mention any sham animals. Therefore, we applied the 
standardized mean difference (SMD) which is also regularly used in clinical meta-analyses55 for both the 
outcome measure ‘infarct size’ and ‘neurological score’. An SMD expresses the difference between the 
groups relative to the standard deviation. Calculation of mean differences56–58 was not possible because of 
the heterogeneity in study designs (i.e. species) and the variety of scales used to determine the outcomes. 
The studies of NOX1 and NOX2 were analyzed separately. In case different measures of neurobehavioral 
outcomes were reported from the same cohort of animals we pooled the individual effect sizes and used 
this pooled estimate in the overall meta-analysis. Despite anticipated heterogeneity, the individual SMDs 
were pooled whenever possible (starting from two studies or more) to obtain an overall SMD and 95% 
confidence interval.
To account for anticipated heterogeneity, we used the random effects model in which some hetero-
geneity beyond sampling errors is allowed. In order to assess the robustness of our findings and in an 
attempt to explain observed study heterogeneity, we performed a sensitivity analysis and we investi-
gated the effects of excluding the study with permanent ischemia. Meta-analysis was performed using 
Comprehensive Meta Analysis (CMA version 2.0). Forest plots were used to display the mean overall 
effect sizes. Data are expressed as SMD with 95% confidence intervals. For the outcome measure infarct 
size, we assessed the possibility of publication bias by visually evaluating the possible asymmetry in fun-
nel plots59. Using the trim and fill analyses an adjusted intervention effect was calculated60.
pRCT. The preclinical Randomized, Confirmatory (and blinded) animal Trial was performed in paral-
lel at Maastricht University (The Netherlands) and at the University of Würzburg (Germany). All animals 
studies were done in accordance with the approved national animal experimental guidelines and were 
approved by the local animal ethics committees. The objective of the study was to compare the extent of 
neurological damage after stroke in mice with or without NOX2 gene deletion. At each study site, surgery 
and follow-up measurements were performed blinded and animals were operated randomly according 
to an online randomization tool (www.randomizer.org). For a power of 80%, based on a minimal effect 
on infarct size of − 40% and an SD of 30%, the required animal numbers were at least n = 10 per study 
arm. Transient middle cerebral artery occlusion (tMCAO) was performed with an intraluminal filament 
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method as described by Kleinschnitz et al.24. After 60 minutes of ischemia, the filament was withdrawn 
and reperfusion established. Twenty-four hours after induction of the ischemia, mice were scored for 
neurological and motor function. Infarct size was determined using 2, 3, 5-triphenyltetrazolium chloride 
(TTC) staining. For a more detailed description, see the Supplementary Information Methods.
Power analysis. We conducted a post hoc analysis of power in all earlier published studies in Nox2-/y 
mice and stroke. Twelve studies and our own new data were analyzed for their power to detect a dif-
ference of 40% in infarct size. This threshold of 40% difference was based on post-hoc analysis of failed 
clinical trials where preclinical studies showed a 30–40% difference29,61,62. Power was calculated using 
Russ Lenth’s power software, an alpha of 0.05, an effect of 0.4 and a pooled variance [(Lenth, R.V 2006-9, 
java Applets for Power and Sample Size [Computer Software], Retrieved 02-17-2014, from http://www.
stat.uiowa.edu/~rlenth/Power)]. The pooled variance was calculated for 4 different groups according to 
ischemic and reperfusion time: a) long reperfusion time (72 h), b) short reperfusion time (24 h) after 
short ischemia (30 min), c) short reperfusion time (24 h) after medium ischemia (60-75 min), and d) 
short reperfusion time (24 h) after long ischemia (90-120 min). From each individual study, the coeffi-
cient of variation was calculated for both KO and WT values. Taking into account all these values, the 
pooled variance for each group was calculated according to formula (1) here with n the size of the group 
and CV the coefficient of variation (SD/Mean) of the group.
Sp
CV n
n
1
1 1
2
=
∑ × ( − )
∑( − ) ( )
Statistics. Infarct volume data are expressed as mean ± SEM. Statistical differences between mean 
values were determined by Student’s two-tailed t test, using the GraphPad Prism 5.0 software pack-
age. Neurological scores were expressed as median. For discrete variables (behavior and motor function 
scores), the Mann-Whitney U-test was used. A value of P < 0.05 was considered to be statistically signif-
icant. Power calculations were performed by using Russ Lenth’s power and sample size software.
Results
Systematic review and meta-analysis suggest a role of NOX2 in stroke. In preparation for a 
risk of bias and statistical power analysis on pre-clinical animal studies on NOX2 in experimental stroke, 
we first conducted a systematic review63 (for search strategy see Supplementary Table 1, Supplementary 
Fig. 1) followed by a meta-analysis (for study characteristics see Supplementary Table 2)23,24,35–42,53,64,65. 
Heterogeneity was relatively high (I2 = 73%) as expected given the large variations in study designs and 
methodological quality (Supplementary Table 2, Fig. 1). All studies on NOX2 in stroke were conducted in 
mice. One study created a permanent occlusion48 and all studies but six23,37,39,41,53,65 studied neurological 
outcome 24 h after ischemia. Indeed, we found that the reported infarct size for NOX2 KO vs. NOX2 
WT infarct size was significantly smaller (Fig. 2a). NOX2 KO mice also showed a small but significant 
decreased neurological score compared to WT mice (Fig. 2b), which implicates an improved neurolog-
ical function (SMD − 0.67 [− 1,17; − 0,16]; n = 9, p = 0.010). Calculation of mean differences56–58 was 
not possible because of the heterogeneity in study designs (i.e. species) and the variety of scales used to 
determine the outcomes (see Methods).
Most studies on NOX2 in stroke were insufficiently powered. We then analyzed whether those 
studies that were included in the systematic review were sufficiently powered to detect an effect size of 
Figure 1. Risk of bias and reporting quality of NOX2 studies, averaged per item. Items, i.e. risks of bias 
are listed on the left. Open bars indicate a low risk of bias; closed, a high risk; hatched bars, an unclear risk. 
Items 1 and 3 scored reporting.
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40%, which is considered a minimum to be subsequently translationally relevant (see Methods). Since 
especially in small studies the observed variance is not a precise estimate of the true variance, we com-
puted pooled variances. For four different groups (short ischemia time, medium ischemia time, long 
ischemia time and long reperfusion time), we found these calculated pooled variances to be 0.44, 0.60, 
0.29 and 0.43, respectively. With these and the number of animals described in each study, we calculated 
the power to detect a difference of at least 40% (Table 1). Most notably, none of the studies reached a 
sufficient level of power (1-ß ≥ 0.08), with the exception of our own earlier study (1-ß = 0.95), which 
had shown no effect for NOX224.
Poor reporting and risk of bias in studies on NOX2 in stroke. To assess the quality of the 
included papers, we conducted a risk of bias analysis. However, as a result of poor reporting in most 
animal studies, we also assessed a few reporting criteria (item 1 and 3). Figure 1 shows this risk of bias 
results for the NOX2 studies. Only a single study reported randomization. Also, in only 15% of the 
studies it was clear that at baseline groups were similar with respect to age, weight, and supplier. None 
of the papers mentioned whether or not they housed the animals randomly and used a random order to 
assess the outcomes. Only four papers reported blinding at any level, for two of these four studies, both 
the treatment and assessment, for the other two only the outcome assessment was blinded. Overall, the 
risk of bias analysis showed that reporting essential details of the animal stroke studies is poor and there 
seems to be a substantial risk of bias.
Publication bias leads to an overestimation of the NOX2 effect size in stroke. In addition 
to insufficient power, publication bias has been shown to influence preclinical study results. To identify 
a possible publication bias for the outcome ‘infarct size’, we created a funnel plot10,60. Figure  3 shows 
Figure 2. Meta-analysis of the overall effect of NOX2 on infarct size and neurological score in 
experimental stroke. Studies included are shown on the left and analyzed in two forest plots, either without 
(left section) or with (right section) the data of the here presented randomized, confirmatory, blinded study. 
Subgroups within one study are depicted separately with the following coding: a, female gender; b, male 
gender; c, short ischemic time; d, medium ischemic time; e, long ischemic time. The upper half a, contains 
data for the effect of NOX2 on infarct size (IS); the lower half b, on neurological score (NS). Displayed are 
the standardized mean difference (SMD), 95% confidence intervals and relative weight of the individual 
studies. The diamond indicates the global SMD and its 95% confidence interval.
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that it is likely that several small studies reporting larger infarcts in NOX2 KO mice are missing from 
the literature. This may indicate an overestimation of the overall effect (SMD − 0,66 [− 1,20; − 0,14]) as 
calculated in the meta- analysis and questions the significance of NOX2. Moreover, reporting of essen-
tial details of the animal stroke studies was poor and there was a substantial risk of bias (Fig. 1). Only 
31% of the studies reported on blinding of the outcome measures. In addition, just 15% of the studies 
described whether they randomized the allocation of the animals to the various groups. None of the 
papers described the method for randomization. Blinding and randomization are key quality measures 
of experimental design of intervention studies, and are known to cause bias54.
Reference Gender
Duration 
ischemia 
(min)
Time of 
sacrifice 
(h)
Infarct size
Power 
for 40% 
effect
NOX2 WT NOX2 KO
N
Mean 
(mm 3) SD CV N
Mean 
(mm3) SD CV
Reperfusion time 24 h, short ischemia
 Brait38 M 30 24 8 58,63 32,16 0,55 10 30,04 28,37 0,94 26
F 30 24 7 24,93 17,04 0,68 10 42,69 17,01 0,40 24
 De Silva35 M 30 24 15 36,30 13,20 0,36 7 14,70 10,20 0,69 28
Reperfusion time 24 h, middle long ischemia
 Chen40 M 75 24 5* 53,90 19,23 0,36 5* 26,00 10,73 0,41 54
 Chen41 M 75 24 3* 50,00 7,79 0,16 3* 28,50 3,93 0,14 29
 Kleinschnitz24 M 60 24 10 78,70 19,50 0,25 18 79,18 20,90 0,26 95
 McCann53 M 60 6 5 12,90 4,30 0,33 5 9,50 2,10 0,22 59
M 60 24 5 35,60 4,30 0,12 6 15,10 3,10 0,21 54
Reperfusion time 24 h, long ischemia
 Liu49 M 90 24 5 38,00† 2,00 0,05 5 25,00† 5,00 0,20 16
 Kahles37 M 120 24 13 83,88 41,92 0,50 14 43,20 38,23 0,88 41
 Tang36 M 120 24 6 163,83 35,59 0,22 4 69,41 35,66 0,51 15
 Walder23 M 120 24 10 54,00 33,52 0,62 13 29,10 20,19 0,69 35
 Wang42 M 120 24 8 35,25 9,50 0,27 8 19,38 8,55 0,44 25
Reperfusion time 72 h
 Chen40 M 75 72 5* 106,20 27,95 0,26 5* 52,00 26,39 0,51 25
 Chen41 M 75 72 3* 86,00 16,00 0,19 3* 55,00 16,16 0,29 14
 Kunz39 M 25 72 5* 52,00 24,40 0,47 5* 20,10 11,70 0,58 25
 McCann53 M 90 72 5 28,77 14,14 0,49 8 20,92 9,28 0,44 31
Reperfusion time 24 h, middle long ischemia, including current study
 Chen40 M 75 24 5* 53,90 19,23 0,36 5* 26,00 10,73 0,41 48
 Chen41 M 75 24 3* 50,00 7,79 0,16 3* 28,50 3,93 0,14 26
 Kleinschnitz24 M 60 24 10 78,70 19,50 0,25 18 79,18 20,90 0,26 92
 McCann53 M 90 6 5 12,90 4,30 0,33 5 9,5 2,10 0,22 53
M 90 24 5 35,60 4,30 0,12 6 15,10 3,10 0,21 48
 Multicentre F 60 24 10 99,77 33,12 0,33 19 75,44 32,99 0,44 97
M 60 24 21 76,76 10,53 0,14 14 84,66 9,31 0,11 93
All 60 24 41 89,00 32 0,36 51 80,00 31,00 0,39 100
Table 1. Power analysis of experimental stroke studies validation the role of NOX2 in Nox2-/y and WT 
mice. To assess the power of already published studies, original data sets were requested from the authors. 
Means, SD’s and numbers of animals were extracted from the original data or, if original data sets could not 
be obtained, from the text or figures using ‘universal desk top ruler’ software. If only the SEM was reported, 
the SD was calculated using formula (2). SD n SEM SD n SEM= × = ⋅  (2). For four different groups, 
pooled variances were used to calculate the power for detecting a 40% difference was calculated using the 
Russ Lenth’s power and sample size software (http://homepage.stat.uiowa.edu/~rlenth/Power/index.html). 
The power for the ‘reperfusion time 24 h, middle long ischemia’ group were recalculated using the newly 
available data from the current pRCT study. * Lowest number of number range † Infarct size reported as 
percentages.
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A randomized, confirmatory, blinded, and fully powered pre-clinical trial excludes a relevant 
role for NOX2 in stroke. The literature on NOX2 in stroke fulfilled all criteria to justify conducting 
the first pre-clinical, randomized, confirmatory trial, powered for a minimally relevant effect of 40% 
reduction of infarct volume, with the aim to provide reliable target validation data. A priori sample size 
calculation showed that at least 10 animals would be necessary in each study arm, which we exceeded 
with n = 41 WT and n = 51 NOX2 KO mice. Importantly, 24 h after transient middle cerebral artery 
occlusion (tMCAO), neither infarct distribution (Fig.  4A), infarct size (Fig.  4B), nor neurofunctional 
parameters such as the Bederson score (Fig.  4C) or the Grip test (Fig.  4D) were significantly different 
between NOX2 KO (n = 51) and WT (n = 41) mice. If one was to examine the possible difference in 
infarct size of − 10% in NOX2 (for which our study was not powered), a much larger study with n = 202 
animals per study arm would be needed (based on a power of 1 − β = 0.08, and an α of 0, 05, a standard 
deviation of 30%, an effect of 10%, and an average reported acute mortality rate of 30%). The use of 404 
animals to clarify such a small and translationally insignificant effect would be ethically non-justifiable.
With respect to stroke and NOX, gender-specific effects have been reported66. In our study, a sub-group 
analysis showed in male NOX2 KO mice a larger than average infarct size reduction of 25% (see Fig. 4B, 
second data set), which reached significance (p = 0.04) but was underpowered (1 − β = 0.68). In none of 
the subgroups did we find any translationally relevant improvements, neither in neurological behavior 
or motor function (see Fig. 4C,D).
Our revised meta-analysis suggests an even lower effect size, no neurological improve-
ment and persisting publication bias. To test whether these new findings would affect our above 
meta-analysis (see Fig. 2, left data set) we re-ran the extended data set (see Fig. 2, right data set). Still, 
NOX2 appeared to significantly decrease the infarct size (Fig.  2a SMD − 1.15 [− 1.67; − 0.63]; n = 20; 
p = 0.000). However, the effect was now smaller and even after including our new study results, a pub-
lication bias still appeared to overestimate our overall effect estimation (Fig. 5). Importantly and inde-
pendently of infarct size, the effect of NOX2 KO on the neurological score was no longer significant 
(SMD − 0.37 [− 0.79; 0.06]; n = 12; p = 0.094). Thus even if a small effect on the surrogate infarct size 
would ever be shown with sufficient power, we can predict it will not translate into any significant neu-
rological outcome improvement. Clearly, this conclusion is a definitive counter-argument against any 
further clinical development of this target.
Discussion
Here we provide a feasible solution to a major problem of current biomedical research, the irrepro-
ducibility of pre-clinical results leading subsequently to translational failures at the path to the clinic. 
We show that adopting our SR-MA-pRCT-MA approach to a more large-scale, collaborative way of 
Figure 3. Funnel plot asymmetry suggesting the presence of publication bias and an overestimation of 
the overall effect size of NOX2 in stroke. The Y-axis represents precision; the X-axis effect size of individual 
studies. The funnel plot is based on the fact that precision in estimating the underlying treatment effect will 
increase as the sample size of component studies increases. Using the trim and fill analyses the intervention 
effect is adjusted for possible missing studies (filled red symbols) amongst published data (open symbols). 
The asymmetry suggests that studies showing larger infarcts in NOX2 KO mice in experimental stroke are 
missing. These would otherwise shift the mean (open diamond) towards a smaller or no overall effect of 
NOX2 (closed diamond).
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research will improve research quality and enhance the validity of pre-clinical decision-making on ther-
apeutic targets. Undoubtedly, it also challenges current funding and career reward systems which value 
rather individual than team achievements. We chose to examine stroke as an example as this is an area 
of extreme medical need with probably one of the lowest translational success rates in biomedicine. 
However, we feel confident that what we show applies most likely to many other fields and many other 
claimed pharmacological targets.
Figure 4. Infarct size and neurological function in NOX2 and WT mice. Mice of both genders and 
between 6–20 weeks old were subjected to tMCAO. (A) TTC stainings of three sequential coronal brain 
sections on day 1 after tMCAO that were representative for each subgroup: young (6–10 week old), adult 
(18–20 week old) male, and adult female NOX2 KO and WT mice. The TTC staining colors viable tissue 
red, while infarcted tissue stays white. (B) Bar graphs of mean infarct volumes ± SEM from WT (open bar) 
and NOX2 KO mice (closed bars). (C) Scatter plot and median of neurodeficit Bederson scores on day 1 
after tMCAO, ranging from 0 (normal) to 5 (severe), from WT (open symbols) and NOX2 KO mice (closed 
symbols). (D) Scatter plot and median of grip test scores, ranging from 0 (severe deficit) to 5 (normal) from 
WT (open symbols) and NOX2 KO mice (closed symbols). The asterisk, *, indicates statistical significance 
(P < 0.05, t-test) for the infarct size in the subgroup adult male NOX2 versus WT; however, this group was 
insufficiently powered to allow the detection of a difference. Combined analysis did not show a significant 
difference for any of the parameters.
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A profound body of pre-clinical literature seemed to suggest that NOX2 is a therapeutic target in 
stroke whilst some data had argued clearly against this. We hypothesized that this may be a case of 
insufficient pre-clinical validity on either side, which would qualify to conduct a pRCT. After contacting 
every group that had published in this field on this pharmacological target we conducted a systematic 
review. Indeed our subsequent meta-analysis suggested that a small effect of NOX2 on infarct size and 
neurological score might exist but that there was also a significant publication bias. In the present case, 
complete reporting of data would have shifted the true effect size towards a lower or no role of NOX2 in 
stroke. Reporting of essential experimental parameters was also rather poor. Failure in reporting these 
details is known to skew the interpretation of study results and subsequent translation into clinical ben-
efits. Another criterion that was fulfilled in all studies that reported significant effects was the lack of 
statistical power to detect a relevant infarct size reduction of 40%62, which is a soft target as this will still 
not ensure clinical benefit67–70. The true threshold is likely to be even higher, but in the absence of any 
successful translation of pre-clinical stroke research in the past 20 years14, this cannot be determined21.
Having established that the literature on NOX2 in stroke fulfilled all typical criteria for insufficient 
pre-clinical target validation (publication bias, poor methodological quality and lack of power), we here 
present the first SR-MA-pRCT-MA approach to validate a single intervention or, in this case, target vali-
dation. Based on its outcome data, a NOX2 KO does not improve neurological outcome and has an effect 
on infarct size that was too small to be determined by a trial powered for 40% reduction. Conducting 
another pRCT using > 400 animals would be required to determine whether indeed a 10% infarct size 
reduction occurs; this however would be considered translationally irrelevant (see above examples and 
threshold) and thus unethical.
Moving to the SR-MA-pRCT-MA approach as the new quality standard, at least for pharmacological 
target validation, will in all likelihood exceed individual laboratories’ capacity. Thus conducting such 
studies in a more collaborative manner, meaning multi-center trials, seems to be the logical way forward. 
In fact, for other targets, including very late antigen 4 (VLA-4)71 and transient receptor potential cation 
channel, subfamily M, member 2 (TRPM2; PMID: 25236871)72, such trials are currently under way 
already. A website has been launched (www.p3pt.de) as an invitation to the community to provide their 
position on pRCTs and potential suggestions how those should be organized and performed21.
Importantly, implications reach further. The studies that we have analyzed were conducted in Korea, 
Germany, USA, Australia, and the Netherlands. Animal ethics regulations differ, but at least for the 
European Community it can be said that in recent years there has been a massive push towards ‘The 
Three Rs’, reduction, replacement, and refinement73. However, reducing the number of animals below the 
limits of statistical power will lead to underpowered and in the end meaningless pre-clinical data sets. 
Whilst we strongly support the goal to achieve pre-clinical evidence with the least amount of animal 
sacrifice, the use and reporting of a power calculation is essential to the proper conduct of confirmatory 
animal studies. Other study formats, e.g. in earlier pre-clinical stages are important as well; however, they 
should describe themselves as exploratory and not make statements on target validity.
Figure 5. Updated funnel plot with the data from the current trial. Funnel plot asymmetry still suggests 
the presence of publication bias and an overestimation of the overall effect size of NOX2 in stroke. Using 
the trim and fill analyses, the intervention effect is adjusted for possible missing studies (filled red symbols) 
amongst published and present data (open symbols). Studies showing larger infarcts in NOX2 KO mice and 
thus a smaller or no effect of NOX2 in experimental stroke, are still missing. For further explanations see 
Fig. 3.
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Finally, funding agencies and journals may need to adapt. Funding and career incentives typically 
reward individuals, whereas pRCTs require team approaches. Journals will need to equally accept for 
publication well-conducted (e.g. statistically powered) negative findings, so that the literature is truly 
representative of the science. To ensure that such findings are accessible, even if not submitted for publi-
cation, a rather far-reaching but effective measure would be to require pre-registration of animal exper-
iments, whether they were conducted as pRCTs or just pilots, similar to requirements for clinical trials. 
Registration would be a pre-requisite for ethics approval and include the obligation to subsequently enter 
the data into a publicly available database. This will reduce the efforts to conduct MAs as an interim 
surrogate for pRCTs. However, conducting fully powered pRCTs, including detailed reporting and sub-
sequent MA is clearly the way forward.
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